Gusacitinib
CAS No. : 1425381-60-7
(Synonyms: ASN-002)
| Size | Price | Stock |
|---|---|---|
| 5mg | $100 | In-stock |
| 10mg | $157 | In-stock |
| 25mg | $250 | In-stock |
| 50mg | $450 | In-stock |
| 100mg | $750 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-103018 |
| M.Wt: | 460.53 |
| Formula: | C24H28N8O2 |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma[1][2].
IC50 & Target:IC50: 5-46 nM (SYK, JAK)[2].
In Vitro:Gusacitinib shows anti-proliferative activity in a broad panel of human cancer cell lines including DHL6, DHL4, OCI-LY10, H929, Pfeiffer, HT-1376, and Lovo, suggesting activity in both solid and hematological tumor types[3].
In Vivo:Gusacitinib exhibits significant efficacy in inhibiting tumor growth (>95%), in a multiple myeloma (H929) xenograft model[3].
Gusacitinib significantly delays the onset of hind limb paralysis in the human erythroleukemia (HEL) mouse model[3].
Gusacitinib shows a favorable safety profile in rat and dog toxicology studies[3].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Gusacitinib
- Cat. No.:
- HY-103018
- Quantity:
Your information is safe with us.